GB2206788B - 5 ht-3 antagonist for the treatment or reduction of dependence - Google Patents

5 ht-3 antagonist for the treatment or reduction of dependence

Info

Publication number
GB2206788B
GB2206788B GB8816298A GB8816298A GB2206788B GB 2206788 B GB2206788 B GB 2206788B GB 8816298 A GB8816298 A GB 8816298A GB 8816298 A GB8816298 A GB 8816298A GB 2206788 B GB2206788 B GB 2206788B
Authority
GB
United Kingdom
Prior art keywords
antagonist
dependence
reduction
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
GB8816298A
Other languages
English (en)
Other versions
GB8816298D0 (en
GB2206788A (en
Inventor
Assunta Imperato
Dietmar Roemer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of GB8816298D0 publication Critical patent/GB8816298D0/en
Publication of GB2206788A publication Critical patent/GB2206788A/en
Priority to GB9104599A priority Critical patent/GB2240476B/en
Application granted granted Critical
Publication of GB2206788B publication Critical patent/GB2206788B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB8816298A 1987-07-11 1988-07-08 5 ht-3 antagonist for the treatment or reduction of dependence Expired - Lifetime GB2206788B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9104599A GB2240476B (en) 1987-07-11 1991-03-05 5 ht-3 antagonists for the prevention or reduction of dependence

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3722959 1987-07-11
DE3735719 1987-10-22
CH451087 1987-11-19

Publications (3)

Publication Number Publication Date
GB8816298D0 GB8816298D0 (en) 1988-08-10
GB2206788A GB2206788A (en) 1989-01-18
GB2206788B true GB2206788B (en) 1992-03-25

Family

ID=27174878

Family Applications (2)

Application Number Title Priority Date Filing Date
GB8816298A Expired - Lifetime GB2206788B (en) 1987-07-11 1988-07-08 5 ht-3 antagonist for the treatment or reduction of dependence
GB9104598A Expired - Lifetime GB2240475B (en) 1987-07-11 1991-03-05 5 ht-3 antagonist for the prevention or reduction of dependence

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB9104598A Expired - Lifetime GB2240475B (en) 1987-07-11 1991-03-05 5 ht-3 antagonist for the prevention or reduction of dependence

Country Status (18)

Country Link
US (1) US5039680A (enExample)
EP (1) EP0302008A3 (enExample)
JP (1) JPS6431729A (enExample)
KR (1) KR890001537A (enExample)
AT (1) AT401615B (enExample)
AU (3) AU618008B2 (enExample)
BE (1) BE1004835A5 (enExample)
DE (1) DE3822792C2 (enExample)
DK (1) DK385388A (enExample)
FR (1) FR2617713A1 (enExample)
GB (2) GB2206788B (enExample)
HU (1) HU206042B (enExample)
IT (1) IT1226632B (enExample)
MY (1) MY103536A (enExample)
NL (1) NL8801733A (enExample)
PH (1) PH27002A (enExample)
PT (1) PT87958B (enExample)
SE (1) SE8802570L (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198447A (en) * 1986-11-21 1993-03-30 Glaxo Group Limited Medicaments
EP0279114B2 (en) * 1986-11-21 1995-08-23 Glaxo Group Limited Medicaments for the treatment or prevention of the withdrawal syndrome
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
NZ230068A (en) * 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
US5166341A (en) * 1988-07-29 1992-11-24 Dainippon Pharmaceutical Co., Ltd. 6-amino-1,4-hexahydro-1H-diazepine derivatives
GB8820650D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US5276050A (en) * 1989-08-01 1994-01-04 Glaxo Group Limited Medicaments
WO1993000074A1 (en) * 1991-06-26 1993-01-07 Sepracor, Inc. Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
JPH05310732A (ja) * 1992-03-12 1993-11-22 Mitsubishi Kasei Corp シンノリン−３−カルボン酸誘導体
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
US6109269A (en) * 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282874A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
MXPA04000779A (es) * 2001-08-24 2004-04-20 Pharmacia & Up John Company 7-aza[2.2.1]bicicloheptanos sustituidos con arilo para el tratamiento de enfermedades.
US6569887B2 (en) 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
BR0212101A (pt) 2001-08-24 2004-08-24 Pharmacia & Up John Company 7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças
CA2460075A1 (en) * 2001-09-12 2003-03-20 Donn Gregory Wishka Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
CZ2004408A3 (cs) 2001-10-02 2005-03-16 Pharmacia & Upjohn Company Azabicyklicky substituované kondenzované heteroarylsloučeniny
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
WO2003040147A1 (en) * 2001-11-08 2003-05-15 Pharmacia & Upjohn Company Azabicyclic-substituted-heteroaryl compounds for the treatment of disease__________________________________________________________________________________________________________________________
JP2005510523A (ja) 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
AU2003212882A1 (en) 2002-02-01 2003-09-02 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
US6852716B2 (en) 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease
JP2005523288A (ja) * 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
CA2476624A1 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
MXPA04007083A (es) * 2002-02-20 2004-10-29 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
US6864261B2 (en) * 2002-05-02 2005-03-08 Euro-Celtique S.A. Therapeutic agents useful for treating pain
DE60318875T2 (de) * 2002-06-28 2009-01-15 Euro-Celtique S.A. Therapeutische piperazin-derivate für die behandlung von schmerzen
US7262194B2 (en) * 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
WO2004013137A1 (en) * 2002-08-01 2004-02-12 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
BR0315056A (pt) * 2002-11-01 2005-08-16 Pharmacia & Upjohn Co Llc Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
ES2322707T3 (es) * 2003-07-03 2009-06-25 Euro-Celtique S.A. Derivados de 2-piridina alquino utiles para tratar el dolor.
PL1867644T3 (pl) 2003-07-24 2009-10-30 Euro Celtique Sa Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
ES2327684T3 (es) 2003-07-24 2009-11-02 Euro-Celtique S.A. Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor.
EP1648878B9 (en) 2003-07-24 2011-03-16 Euro-Celtique S.A. Piperidine compounds and pharmaceutical compositions containing them
MXPA06001331A (es) * 2003-08-01 2006-05-04 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor.
SI1664041T1 (sl) 2003-09-22 2008-12-31 Euro Celtique Sa Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
MXPA06003123A (es) * 2003-09-22 2006-05-31 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor.
ES2322907T3 (es) * 2003-12-30 2009-07-01 Euro-Celtique S.A. Piperazinas utiles para el tratamiento de dolor.
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
ZA200801825B (en) 2005-07-27 2009-12-30 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
CA2685121A1 (en) * 2007-04-27 2008-11-06 Purdue Pharma L.P. Therapeutic agents useful for treating pain
WO2008153937A2 (en) * 2007-06-06 2008-12-18 Dov Pharmaceutical, Inc. Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US8697722B2 (en) * 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
WO2011085389A1 (en) * 2010-01-11 2011-07-14 Astraea Therapeutics, Llc Nicotinic acetylcholine receptor modulators
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN115368356B (zh) 2013-12-20 2025-05-09 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0204954A2 (en) * 1985-05-06 1986-12-17 Sandoz Ag Use of dopamine agonists for the manufacture of a medicament for the treatment of psychostimulant addiction
EP0279114B1 (en) * 1986-11-21 1992-03-25 Glaxo Group Limited Medicaments for the treatment or prevention of the withdrawal syndrome

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59004A0 (en) * 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
BE897117A (fr) * 1982-06-29 1983-12-23 Sandoz Sa Nouveaux derives de la piperidine leur preparation et leur utilisation comme medicaments
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
DE3429830A1 (de) * 1983-08-26 1985-03-07 Sandoz-Patent-GmbH, 7850 Lörrach Automatische carbonsaeure- und sulfonsaeureester oder -amide
DE3445377A1 (de) * 1983-12-23 1985-07-04 Sandoz-Patent-GmbH, 7850 Lörrach Carbocylische und heterocyclische carbonsaeureester und -amide von ueberbrueckten und nicht ueberbrueckten cyclischen stickstoffhaltigen aminen oder alkoholen
PH22672A (en) * 1984-01-25 1988-11-14 Glaxo Group Ltd Imidazolylmethyltetrahydrocarbazolone derivatives, composition and method of use thereof
EP0385517B1 (en) * 1985-03-14 1993-04-14 BEECHAM GROUP plc Medicaments for the treatment of emesis
DE3687080T2 (de) * 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8520616D0 (en) * 1985-08-16 1985-09-25 Beecham Group Plc Compounds
GB8701494D0 (en) * 1987-01-23 1987-02-25 Glaxo Group Ltd Chemical compounds
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
GR871809B (en) * 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
NZ226032A (en) * 1987-09-03 1991-12-23 Glaxo Group Ltd 2-(imidazolylmethyl)-pyrido or-azepino(4,3-b)indole-1(2h)-one derivatives; preparatory processes and pharmaceutical compositions
ZA886585B (en) * 1987-09-08 1990-05-30 Lilly Co Eli Specific 5-ht,antagonists
GB8723157D0 (en) * 1987-10-02 1987-11-04 Beecham Group Plc Compounds
US4985420A (en) * 1987-12-10 1991-01-15 Duphar International Research B.V. 1,7-annelated indolecarboxylic acid esters and -amides
US5116984A (en) * 1988-04-07 1992-05-26 Glaxo Group Limited Imidazole derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0204954A2 (en) * 1985-05-06 1986-12-17 Sandoz Ag Use of dopamine agonists for the manufacture of a medicament for the treatment of psychostimulant addiction
EP0279114B1 (en) * 1986-11-21 1992-03-25 Glaxo Group Limited Medicaments for the treatment or prevention of the withdrawal syndrome

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bull. Acad. Natt. Med. (Paris)107 (8), 1045-50 (1986) *
J. Pharmac. and Exp. Therap. (1986)239 219-228 *
J. Psychopharmacol. (Oxford)1 (2), 101-8 (1987) *

Also Published As

Publication number Publication date
DK385388A (da) 1989-01-12
PT87958B (pt) 1995-03-01
IT8848172A0 (it) 1988-07-11
US5039680A (en) 1991-08-13
AU8563091A (en) 1991-12-12
NL8801733A (nl) 1989-02-01
AU1892088A (en) 1989-01-12
FR2617713A1 (fr) 1989-01-13
HUT50038A (en) 1989-12-28
IT1226632B (it) 1991-01-28
JPS6431729A (en) 1989-02-02
EP0302008A2 (en) 1989-02-01
MY103536A (en) 1993-07-31
KR890001537A (ko) 1989-03-27
SE8802570L (sv) 1989-03-28
AU618008B2 (en) 1991-12-12
DE3822792A1 (de) 1989-01-19
AT401615B (de) 1996-10-25
BE1004835A5 (fr) 1993-02-09
AU633762B2 (en) 1993-02-04
PH27002A (en) 1993-02-01
DK385388D0 (da) 1988-07-08
HU206042B (en) 1992-08-28
DE3822792C2 (de) 1997-11-27
GB8816298D0 (en) 1988-08-10
SE8802570D0 (sv) 1988-07-08
EP0302008A3 (en) 1992-12-23
GB2240475B (en) 1992-03-18
GB2206788A (en) 1989-01-18
AU643075B2 (en) 1993-11-04
GB2240475A (en) 1991-08-07
AU8562891A (en) 1991-12-05
GB9104598D0 (en) 1991-04-17
PT87958A (pt) 1989-06-30
FR2617713B1 (enExample) 1994-08-19

Similar Documents

Publication Publication Date Title
GB2240475B (en) 5 ht-3 antagonist for the prevention or reduction of dependence
GB2210266B (en) Dosage form
GR900300093T1 (en) Composition for the treatment of erectile dysfunction
ZA887889B (en) Process for the manufacture of 1,1,1-trifluorodichloroethylene and 1,1,1,2-tetrafluorochloroethylene
EP0188081A3 (en) Use of paroxetine for the treatment of obesity
ZA857081B (en) Composition for the treatment of allergy
GB8708040D0 (en) Treating surfaces
ZA885365B (en) Process for the reduction of ketones
DE3568700D1 (en) Anti-ulcer means for the treatment of abscesses
GB2165453B (en) Pharmaceutical agent for the local treatment of psoriasis
GB2240476B (en) 5 ht-3 antagonists for the prevention or reduction of dependence
EP0232761A3 (en) Tool for the treatment of surfaces or the like
GB2145082B (en) Process for the preparation of 2, 3-dihydro-4h-1-benzopyran-4-one and 2,3,5,6,7,8-hexahydro-4h-1-benzo-pyran-4,5-dione derivativesss
IL87546A0 (en) Improved method for the preparation of anilinofumarate
EP0333490A3 (en) Composition for the treatment of hepatopathy composition for the treatment of hepatopathy
GR3000306T3 (en) Composition for the treatment of infections
ZA885123B (en) Pest-combating agents based on derivatives of 2,3-diaminomaleonitrile
EP0297447A3 (en) Method for the preparation of 2-cyclopentenones
ZA853759B (en) Tetrahydronaphthalenols for the treatment of hypertension
IL88566A (en) Composition for the reduction of phlebectasiae and its preparation
GB2201688B (en) The use of mixtures comprising difluorotetrachloroethane
EP0412938A3 (en) System for the treatment of contactlenses
PHUM6382Z (en) Composition for the treatment of pimples
HU895550D0 (en) Compositions for the treatment of leishmaniasis
EP0307001A3 (en) Method for the preparation of polycyclic 1,3-thiazolidines

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19980708